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Abstract
Background: Although the diagnostic criteria and pathogenesis of gastrointestinal stromal tumors
(GIST) have recently been elucidated, knowledge of the epidemiology of this malignancy is still
limited. This study examined the incidence of GIST in the province of Modena, including pathologic
features and clinical outcome.
Methods: Gastrointestinal mesenchymal tumors identified by the Modena Cancer Registry
between 1991 and 2004 were analyzed with an immunohistochemical panel that included staining
for CD-117 and PDGFRα. Size, mitotic rate, and other pathologic parameters were recorded. Each
tumor was categorized into National Institutes of Health risk categories (very low, low,
intermediate, and high risk).
Results: One hundred twenty-four cases were classified as GIST. The age-adjusted incidence rate
was 6.6 per million. Seventy-five percent of patients were symptomatic; 34% had a previous or
concomitant history of cancer. High-risk features were present in 47% of cases. Seventy-eight
percent were submitted to radical surgery. After complete resection, the 5-year disease-free
survival rates were 94%, 92%, 100%, and 40% for patients at very low, low, intermediate, and high
risk, respectively. In multivariate analysis, high risk was the main predictor of recurrence.
Conclusion: This population-based study shows that the incidence of GIST in Northern Italy is
comparable to that reported in other European countries. Survival was favorable in lower risk
categories and in most of the resected cases. In our study, resected patients at very low, low, and
intermediate risk had a similar outcome. Our data support the need to consider high-risk patients
after complete surgical resection for treatment with the best available approach.
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The term stromal tumor was first introduced by Mazur
and Clark [1] in 1983 to define a group of gastric mesen-
chymal tumors that were not clearly differentiated by
immunohistochemistry and ultrastructure and that were
previously thought to be derived from smooth muscle of
the gastrointestinal wall. In 1998, Kindblom et al.[2] and
Hirota et al.[3] independently determined that these neo-
plasms are significantly immunoreactive for CD117, a
polyclonal antibody recognizing the type III tyrosine
kinase KIT, which is encoded by the proto-oncogene c-kit.
Since in the normal gastrointestinal tract KIT is exclusively
expressed by the interstitial cells of Cajal (ICC), special-
ized cells that interact with neural and muscular structures
that have a pacemaker activity, the authors suggested that
gastrointestinal stromal tumors (GISTs) might derive
from ICC or from stem cells differentiating toward an ICC
phenotype [2]. Moreover, Hirota et al.[3] demonstrated
gain-of-function mutations involving KIT that result in
ligand-independent KIT receptor activation.
GISTs are the most common gastrointestinal soft tissue
malignancies. They mainly occur in the stomach (60–
70%) and small intestine (20–30%); esophageal, colon,
and rectal GISTs are relatively infrequent. Exceptionally,
GISTs occur in the omentum, mesentery, and retroperito-
neum [4]. The median age of patients with GIST is 60–69
years, and symptoms mainly relate to tumor size and site.
The epidemiology of GISTs reflects increased interest in
the tumors and improved ability to perform exact diagno-
sis. Given that an exact definition of GIST was developed
only quite recently and many cases included in the largest
series are from consultation files, few population-based
studies have highlighted the real incidence and clinico-
pathologic characteristics of GISTs.
The aim of this work was to better define the epidemiol-
ogy and clinicopathologic features of GISTs by examining
all cases of soft-tissue tumors originating from the gas-
trointestinal tract that were diagnosed in the province of
Modena (Italy) between 1991 and 2004. We reviewed
these cases for pathologic features, risk stratification, and
clinical outcome.
Methods
We considered all cases of gastrointestinal soft tissue and/
or spindle cell tumor diagnosed in residents of the prov-
ince of Modena (population 633,993 at 2001 census)
between 1991 and 2004. Cases were identified using the
Modena Cancer Registry database and the archival files of
the Section of Pathologic Anatomy of the University of
Modena and Reggio Emilia.
Two pathologists (GR and RV) used a multi-headed
microscope to review all the hematoxylin-eosin stained
slides available for each tumor (mean, 5.5; range, 1–15).
In addition, several 4-µm-thick sections obtained from a
representative formalin-fixed and paraffin-embedded
block of each tumor were cut for immunohistochemical
analysis.
Immunohistochemistry was performed using an auto-
mated immunostainer (Benchmark, Ventana, Tucson,
AZ). All cases were tested with the following panel of anti-
bodies: CD117 (polyclonal, A4502; Dako, Glostrup, Den-
mark; 1:200 dilution; no antigen retrieval), PDGFRα
(polyclonal, sc-338; Santa Cruz Biotechnology, Santa
Cruz, CA; 1:150 dilution; microwave treatment), smooth-
muscle actin (monoclonal, 1A4; Biogenex, San Ramon,
CA; 1:20; no antigen retrieval), desmin (monoclonal,
D33; Dako; 1:10; microwave treatment), S100 (polyclo-
nal, RB044-A; NeoMarkers, Fremont, CA; 1:5; no antigen
retrieval), and CD34 (monoclonal, QB-END/10; Novo-
castra, Newcastle upon Tyne, UK; 1:40; microwave treat-
ment) and cytokeratins (monoclonal, MNF116; Dako;
1:100; protease treatment).
Diagnosis of GIST was established based on clear immu-
nostaining for CD117 or PDGFRα in an adequate clinical
and morphologic context, as previously described [5]. All
cases had sufficient tumor material for immunohisto-
chemical analysis using the above-mentioned panel of
antibodies. All cases were also studied by direct sequenc-
ing PCR of the c-kit exons 9, 11, 13, 17 as well as PDGFRα
exons 12 and 18, as previously described [6]. Briefly, 89
cases showed somatic mutations on c-kit exon 11, 36 on
exon 9, 4 on exon 13 and none at exon 17. PDGFRα muta-
tions were detected in 2 cases (both on exon 12) and 6
cases were "wild-type".
Apart from GIST, we originally reviewed also other 67
neoplasms somehow mimicking GIST, then entering into
its differential diagnosis, as follows: 27 smooth muscle
tumors (18 leiomyomas, 9 leiomyosarcomas); 23
desmoids; 5 spindle cell sarcomatoid carcinomas; 5
inflammatory fibroid polyps (so-called Vanek's tumor); 3
schwannomas; 2 solitary fibrous tumors and 2 inflamma-
tory pseudotumors.
Differential diagnosis was performed by light-microscope
morphologic analysis, immunostaining using the above
panel and in selected cases by means of mutational anal-
ysis.
The tumor risk category was defined by assessing tumor
size and mitotic count, as suggested by the consensus
guidelines of the National Institutes of Health-(NIH-NCI)
workshop[7]. Clinical information was retrieved from
hospital records. Follow-up was performed by active
search of all discharge letters, review of hospital records,Page 2 of 7
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patients' vital status was obtained from official popula-
tion registries.
Survival was calculated from the day of diagnosis until
death or the last time the official population registries
were consulted (June 2006). Disease-free survival was cal-
culated from the date of radical surgery until tumor recur-
rence. Overall survival and disease-free survival were
calculated using the Kaplan-Meier method and analyzed
using the log-rank test. Relative survival was determined
according to the Hakulinen method [8].
Univariate and multivariate Cox proportional hazard
regression analyses were used to analyze factors that may
predict tumor recurrence. All calculations were performed
with the Stata 8 package. Differences were considered sig-
nificant at P-values < 0.05. Patients with metastatic dis-
ease at the time of diagnosis were grouped into the
category "overtly malignant". Analysis of the risk of recur-
rence was performed separately for all patients (including
those with overtly malignant disease) using Fisher's exact
test; multivariate Cox proportional hazard regression
analyses were used to analyze the risk of recurrence for
patients that underwent surgical resection. A cumulative
and smoothed risk of metastases after surgery was calcu-
lated. Receiver operating characteristics methodology [9]
has been used to evaluate the ability of Fletcher's score in
individuate risk of recurrence after resection, overall
metastases, and death.
All information were collected and used to perform anon-
ymous and aggregate statistical analysis. According to the
Italian Laws, approval by a formal ethics committee is not
required for this type of study.
Results
Diagnosis of GIST was established in 137 cases, 124 of
whom were resident in the province of Modena. Only
these 124 patients were included in the analysis. Sixty-six
of these patients (53.2%) were men, and 58 (46.8%) were
women. The median age at presentation was 69 years
(range: 30–90 years). The most common primary site was
the stomach (63% of all GISTs), followed by the small
intestine, retroperitoneum, colon-rectum, esophagus, and
anus (Table 1). Overall, GISTs represented 0.2% of all
invasive cancers for both genders. Moreover, they
accounted for 1.8% of all stomach cancers and 13% of all
cancers arising in the small intestine. The crude incidence
rate was 1.42 per 100,000, 1.55 per 100,000 for men, and
1.30 per 100,000 for women. The age-standardized rate
(ASR) according to the world standard population was
0.66 per 100,000 (men: 0.84 per 100,000, women: 0.49
per 100,000).
One hundred ten tumors were KIT positive (88.7%) while
14 GISTs were KIT negative. In these tumors, the neoplas-
tic cells immunoreacted for PDGFRα and in 2 a PDGFRα
mutation was found. We also noted mutually exclusive
expression and mutational set-up for c-kit and PDGFRα.
The most frequent symptoms were abdominal pain
(36%), gastrointestinal bleeding (25%), worsening of
general condition (24%), and dyspepsia (16%) (Table 1).
Thirty-one patients (25%) were asymptomatic. In 39
patients (31.5%), GIST was incidentally discovered dur-
ing endoscopy or laparotomy performed for other reasons
such as colon polyposis or synchronous gastrointestinal
cancer. Forty-two patients (33.9%) had a previous history
of cancer.
Ninety-seven patients (78.2%) underwent radical surgery,
while 27 patients (21.8%) were unresectable due to dif-
fuse metastatic disease at diagnosis. Eighty-three GISTs
(66.9%) were of spindle-cell morphology, 19 cases
(15.3%) were epithelioid, and 17 cases (13.7%) were of
mixed histotype. In the remaining cases (4%), the small
bioptic specimen did not permit exact assessment of his-
topathologic features.
Table 1: Summary of results
Number %
Gender 124 100
Male 58 46.7
Female 66 53.2
Age 124 100
≤ 60 years 32 25.8
61–70 years 38 30.6
> 70 years 54 43.5
Anatomical distribution 124 100
Esophagus 2 1.6
Stomach 78 62,9
Small intestine 29 23.4
Colon 4 3.2
Rectum 2 1.6
Anus 1 0.8
Retroperitoneum 8 6.5
Clinical symptom 93 75
Intestinal bleeding 31 25
Abdominal pain 44 35.5
Dyspepsia 20 16.1
Nausea/vomiting 15 12.1
Constipation/diarrhea 11 8.9
Abdominal mass 10 8.1
Worsening general condition 30 24.2
Urologic dysfunction 1 0.8
Iron deficiency anemia 19 15.3Page 3 of 7
(page number not for citation purposes)
BMC Cancer 2007, 7:230 http://www.biomedcentral.com/1471-2407/7/230In resected tumors, the mitotic count was less than 5 per
50 high-power fields (HPF) in 53 patients (54.6%),
between 6 and 10 per 50 HPF in 17 patients (17.5%), and
more than 10 per 50 HPF in 24 patients (24.7%). Tumor
size was distributed as follows: 17 cases (17.5%) were less
than 2 cm, 21 cases (21.6%) were between 2 and 5 cm, 27
cases (27.8%) were between 5 and 10 cm, and 32 cases
(33%) were greater than 10 cm.
The prevalence of patients at very low, low, intermediate,
and high risk according to Fletcher's score were 15.3%,
15.3%, 17.7%, and 51.6%, respectively. Overtly malig-
nant tumors accounted for 29 of 124 GISTs (23%), and
represented 5%, 16%, 23%, and 31% of the cases in the
very low, low, intermediate, and high risk groups, respec-
tively.
The median follow-up for living patients was 63 months.
The overall 5- and 10-year relative survival rates were
65.8% (95% CI: 53.9–76.4%) and 60.4% (95% CI: 43.3–
77.1%), respectively. The 5-year relative survival rates
were 100% (95% CI: 77.9–115%), 90.1% (95% CI: 50.4–
108.2%), 93.2% (95% CI: 54.4–110.3%), and 61.5%
(95% CI: 41.3–78.6%) for patients in the very low, low,
intermediate, and high risk categories, respectively, and
12.4% (95% CI: 2.3–32.5%) for overtly malignant GISTs
(Figure 1).
The 5-year relative survival rates were 84.6% (95% CI: 72–
93.2) for patients treated with radical surgery (N = 97)
and 13.8% (95% CI: 0–30.7%) for those without radical
surgery (N = 27). Table 2 shows the distribution of tumor
recurrence after intervention in the group of 97 patients
treated with complete resection of the primary tumor.
Given the superimposable relapse rate of patients falling
into the very low, low, and intermediate risk groups, all
three risk categories were grouped together into a unique
lower-risk group (LRG), whereas the high-risk group
(HRG) corresponds to the original NIH category (receiver
operating characteristics area: 82.6%). The relapse-free
survival rate was 95% for LRG patients and 40% for HRG
patients, respectively (P < 0.001, Figure 2).
All metastatic events were evaluated with respect to age,
location, mitoses, size, gender, symptoms, and Fletcher's
score by grouping together overtly malignant tumors and
tumors that recurred after resection. In univariate analysis,
location other than the stomach and small intestine,
mitotic count higher than 5 per 50 HPF, and tumor size
greater than 10 cm were associated with increased overall
risk of recurrence. NIH and condensed risk categories also
significantly correlated with recurrence (Table 3). The
multivariate Cox regression model confirmed the inde-
pendent prognostic role of tumor risk category (OR: 12.3,
Table 2: Relapse-free survival (RFS) in 97 patients with complete 
resection of the primary tumor
Number 5-year DFS (%) P-value*
Age
≤ 60 years 26 66 0.953
61–70 years 33 72
> 70 years 38 67
Tumor location
Stomach/small intestine 72 73 0.002
Other 25 36
Mitotic count
< 5 per 50 HPF 56 89 < 0.001
5–10 per 50 HPF 24 80
> 10 per 50 HPF 17 16
Size
< 2 cm 17 100 < 0.001
2–5 cm 21 90
5–10 cm 27 67
> 10 cm 32 39
Gender
Male 53 75 0.420
Female 44 63
Symptoms
Yes 33 73 0.348
No 64 52
Tumor risk category
Very low 18 94 < 0.001
Low 16 94
Intermediate 17 100
High 46 40
Condensed risk group#
LRG 51 95 < 0.001
HRG 46 40
*Fisher's exact test
#LRG, very low, low, and intermediate groups; HRG, high risk group
Relative survival for all patients (N = 124) according to very low (N = 18), low (N = 16), intermediate (N = 17), higk risk (N = 44) and overtly malignant 27) c tegoriesFigure 1
Relative survival for all patients (N = 124) according to very 
low (N = 18), low (N = 16), intermediate (N = 17), higk risk 
(N = 44) and overtly malignant (N = 27) categories.Page 4 of 7
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higher than 5 per 50 HPF (OR: 6.2, 95% CI: 2.3–17.2) and
tumor size greater than 10 cm (OR: 3.3, 95% CI: 1.4–7.6).
Discussion
This is the first population-based epidemiological study
evaluating the features of malignant GIST in Italy. Table 4
shows a summary comparison between our results and
those published in other similar series. Our findings,
based on the Modena Cancer Registry data, indicate an
annual crude incidence rate in the province of Modena of
14.2 new cases per million people. Nilsson et al.[10] esti-
mated the rate at 14.5 per million. Tran et al.[11] esti-
mated the 2000 U.S. census ASR at 6.8 per million, much
lower than that estimated for the province of Modena
(after age adjustment, according to the 2000 U.S. standard
population, the Modena ASR was 9.8 per million, 11.9 per
million in men, and 8.0 per million in women). Recently,
Tryggvason et al.[12] investigated all cases of malignant
GIST diagnosed from 1990 to 2003 in Iceland (300,000
inhabitants) and estimated an overall world ASR of 1.1/
100000. Even more recently, Rubio et al.[13] reported a
population-based study in Girona, Spain (553 000 inhab-
itants) that demonstrated an overall world ASR of 0.65/
100000 from 1994 to 2001. These comparisons show an
incidence similar to that reported in Spain and Sweden.
The difference between Modena and Iceland may relate to
different ability in identifying lower-grade lesions, which
may affect the incidence in the very low-risk and low-risk
categories. Finally, the difference between our results and
those estimated in the U.S. [11] may be due to some pre-
viously observed limitations of the cited U.S. study.
The significant immunoreactivity of GIST to KIT (CD117)
has permitted a new nosologic definition. KIT immunos-
taining is an important method for diagnostic distinction
of GIST from leiomyoma, leiomyosarcoma, and schwan-
nomas, which typically do not exhibit KIT positivity [14].
In our series, most cases were KIT positive. However, the
KIT-negative cases were immunoreactive for PDGFRα,
providing immunohistochemical confirmation that KIT
and PDGFRα exhibit mutually exclusive expression, and
not only mutually exclusive mutations [15]. The fre-
quency of PDGFRα mutations in our series is slightly
higher than that in other series [4] and suggests that the
assessment of both KIT and PDGFRα mutations can be
helpful in establishing a more correct diagnosis.
The clinical presentation of GISTs varies according to the
site and size of neoplasm. In our study, GISTs were mostly
located in the stomach and small intestine. The anatomic
distribution seemed unrelated to patient outcome. The
Table 3: Distribution of metastatic events according to tumor 
and patient characteristics
Number of events/
number of cases
% P-value*
Age
≤ 60 years 14/32 44 0.825
61–70 years 17/38 45
> 70 years 27/54 50
Location
Stomach 32/78 41 0.029
Small intestine 13/29 45
Other 13/17 76
Mitotic rate
< 5 per 50 HPF 12/62 19 < 0.001
5–10 per 50 HPF 16/27 59
> 10 per 50 HPF 30/35 86
Size
< 2 cm 3/20 15 < 0.001
2–5 cm 8/27 30
5–10 cm 15/35 43
> 10 cm 32/42 76
Gender
Male 26/58 45 0.721
Female 32/66 48
Symptoms
Yes 45/93 48 0.678
No 13/31 42
Tumor risk category
Very low 2/19 10 < 0.001
Low 4/19 21
Intermediate 5/22 23
High 47/64 73
Condensed risk group#
LRG 11/60 18 < 0.001
HRG 47/64 73
*Log-rank test
# LRG, very low, low, and intermediate groups; HRG, high risk group
Ten-year relapse-free survival (RFS) for 97 patients with compl te section of primary tumor according to very low (N = 18), low (N = 16), intermediate (N = 17) a d higk (N = 46) risk categoriesFigur 2
Ten-year relapse-free survival (RFS) for 97 patients with 
complete resection of primary tumor according to very low 
(N = 18), low (N = 16), intermediate (N = 17) and higk (N = 
46) risk categories.Page 5 of 7
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versial. In fact, in some studies, GISTs arising in the stom-
ach were less aggressive than GISTs arising in the lower
gastrointestinal tract [16], while other studies found no
differences in outcome[17].
In our series, as also reported in the Swedish study [10],
the majority of large GISTs were detected after the onset of
symptoms, while small GISTs were detected incidentally
during surgery performed for other reasons. Our results
confirm that the most common symptoms (in descending
order of frequency) are abdominal pain, intestinal bleed-
ing, and dyspepsia [18].
Tumor size significantly correlated with mitotic count;
larger tumors usually had higher mitotic counts and were
frequently unresectable. As a result, GIST cases with tumor
size > 10 cm have poorer survival [19]. These two histo-
logic criteria are important to define the biological behav-
ior of a tumor and risk category for prognosis.
Conventional histologic factors do not predict the malig-
nant potential and malignant actions of GISTs. Recently,
the descriptors of the malignant behavior of GISTs,
benign and malignant, were substituted with low, inter-
mediate, and high risk. Our results confirm that prognosis
is significantly better for patients in very low-, low-, and
intermediate-risk categories than for patients in high-risk
categories.
Complete tumor resection is another important factor
related to survival [20,21] In this study, for GISTs with
metastasis or with incomplete resection, survival was poor
after surgery alone. After radical surgery, the majority of
relapses occurred in patients with tumors classified as
high risk. It seems to be no differences between the three
lower risk categories when tumor is resectable while lim-
ited differences can be found when considering metastatic
events in all patients. These distinction and obviously lim-
itations due to the small number of patients should all be
considered when comparing outcome of intermediate risk
category in this study with other series. However, Cox
multivariate analysis demonstrated the clinical usefulness
of both the NIH-NCI and condensed (LRG and HRG) risk
categories. Our data also support an alternative simplified
risk score based on the cumulative contribution of two
prognostic factors: mitotic count higher than 5 per 50 HPF
and tumor size greater than 10 cm.
Conclusion
Early diagnosis and complete resection remain the stand-
ard of care, but high-risk patients must be considered for
enrollment in clinical trials of adjuvant treatment. Our
population-based study suggests that the incidence of
GIST in Italy is comparable to that reported in Spain and
other European countries. However, it will be useful to
perform more population-based studies to obtain more
details about epidemiology and to enable prediction of
the future incidence of these neoplasms.
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